Valneva SE (VLA):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8267)・商品コード:DATA904C8267
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:79
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Valneva SE (Valneva) is a biotech company that develops lifesaving vaccines. The company’s products include IXIARO, a vaccine indicated for the prevention of Japanese encephalitis; and Dukoral, a vaccine indicated for the prevention of cholera and diarrhea; clostridium difficile, lyme, chikungunya, and zika diseases. It provides EB66 cell line, a proprietary embryonic stem cell-based technology which is used for the production of human and veterinary viral and therapeutic vaccines; and IC31, a synthetic vaccine adjuvant. Valneva partners with pharmaceutical and biotech companies to develop products using its proprietary technologies. The company operates in Austria, Sweden, the UK, France, Canada, and the US. Valneva is headquartered in Lyon, France.

Valneva SE (VLA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10
Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Valneva SE, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Valneva to Secure USD18 Million from Funds Managed by Athyrium 13
BliNK Biomedical Raises Funds through Series A Venture Financing 14
Valneva Austria Raises US$30 Million In Venture Financing 15
Private Equity 16
Valneva Raises USD8 Million in First Tranche of Private Equity Investment 16
Partnerships 17
InFlectis BioScience Enters into Licensing Agreement with Valneva 17
Seqirus Enters into Distribution Agreement with Valneva 18
Valneva Enters into R&D Agreement with GlaxoSmithKline 19
Valneva Enters into Distribution Agreement with PaxVax 20
PaxVax Enters into Distribution Agreement with Valneva 21
Valneva Forms Joint Venture with BliNK Therapeutics 22
Licensing Agreements 23
Emergent BioSolutions Enters into Licensing Agreement with Valneva 23
Bavarian Nordic Enters into Licensing Agreement with Valneva 24
Valneva Enters into Licensing Agreement with Jianshun Biosciences 25
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 26
Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 27
Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 28
Valneva to Enter into Licensing Agreement with Pharma Company 29
Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 30
GeoVax Labs Enters into Licensing Agreement with Valneva 31
Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 32
Equity Offering 33
Valneva Raises USD54 Million in Rights Offering 33
Valneva Completes Rights Offering Of Shares For US$53.5 Million 35
Asset Transactions 37
Valneva Sells Clinical Manufacturing Operations Facility To Biological E 37
Acquisition 38
Valneva Acquires Crucell Sweden for USD54 Million 38
Valneva SE – Key Competitors 39
Valneva SE – Key Employees 40
Valneva SE – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Aug 02, 2018: VALNEVA Delivers Strong IXIARO Sales Growth and reports Further Progress on Key R&D Programs in H1 43
May 17, 2018: VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs 47
Mar 22, 2018: VALNEVA Delivers Strong 2017 Financial Results and Advances Key R&D Programs 50
Nov 09, 2017: Valneva Reports Strong Operational Performance for the First Nine Months of 2017 54
Aug 31, 2017: Valneva Reports Robust H1 2017 Financial Results & Major R&D Progress 55
May 11, 2017: VALNEVA Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financial Guidance and Pipeline Outlook for 2017 60
Mar 23, 2017: VALNEVA Reports Best Financial Results in the Company’s History with its First Year of Positive EBITDA in 2016 63
Feb 23, 2017: VALNEVA Reports Strong Q4 and FY 2016 Business Performance; Expects Further Growth in Sales and EBITDA, R&D Progress in 2017 68
Corporate Communications 71
Jun 29, 2018: VALNEVA Announces Successful Outcome of its AGM and Renewal of the Term of Office of its Management Board Members 71
Aug 01, 2017: VALNEVA Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth 72
Product News 73
Apr 10, 2017: Valneva to Present at the 17th World Vaccine Congress in Washington D.C. 73
Clinical Trials 74
Mar 29, 2018: VALNEVA to Present Data on VLA-1601 at the 18th World Vaccine Congress in Washington, D.C. 74
Feb 26, 2018: Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus 75
Other Significant Developments 76
Sep 20, 2018: Valneva announces extension of drawdown period for its existing european investment bank loan 76
Dec 11, 2017: Intercell USA Changes Name to Valneva USA and Expands Commercial Presence 77
Jun 30, 2017: Valneva Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Valneva SE, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Valneva SE, Deals By Therapy Area, 2012 to YTD 2018 9
Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10
Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Valneva to Secure USD18 Million from Funds Managed by Athyrium 13
BliNK Biomedical Raises Funds through Series A Venture Financing 14
Valneva Austria Raises US$30 Million In Venture Financing 15
Valneva Raises USD8 Million in First Tranche of Private Equity Investment 16
InFlectis BioScience Enters into Licensing Agreement with Valneva 17
Seqirus Enters into Distribution Agreement with Valneva 18
Valneva Enters into R&D Agreement with GlaxoSmithKline 19
Valneva Enters into Distribution Agreement with PaxVax 20
PaxVax Enters into Distribution Agreement with Valneva 21
Valneva Forms Joint Venture with BliNK Therapeutics 22
Emergent BioSolutions Enters into Licensing Agreement with Valneva 23
Bavarian Nordic Enters into Licensing Agreement with Valneva 24
Valneva Enters into Licensing Agreement with Jianshun Biosciences 25
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 26
Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 27
Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 28
Valneva to Enter into Licensing Agreement with Pharma Company 29
Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 30
GeoVax Labs Enters into Licensing Agreement with Valneva 31
Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 32
Valneva Raises USD54 Million in Rights Offering 33
Valneva Completes Rights Offering Of Shares For US$53.5 Million 35
Valneva Sells Clinical Manufacturing Operations Facility To Biological E 37
Valneva Acquires Crucell Sweden for USD54 Million 38
Valneva SE, Key Competitors 39
Valneva SE, Key Employees 40
Valneva SE, Other Locations 41
Valneva SE, Subsidiaries 41

List of Figures
Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Valneva SE (VLA):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8267)販売に関する免責事項を必ずご確認ください。
★調査レポート[Valneva SE (VLA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆